Company Directory / Hospital & Health Care
PrivateFor profitHospital & Health CareSwitzerland
GlycoVaxyn
GlycoVaxyn develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology.
- Founded
- 2004 22 years ago
- Staff
- 11-50 2 on LinkedIn
- Followers
- 486 on LinkedIn
- Funding
- $34M as listed, USD
GlycoVaxyn is a private Swiss biotechnology company developing a broad portfolio of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technology.
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed. 2 people list it on LinkedIn.
Age
22 years old.
Reach
No web traffic ranking listed. 486 followers on LinkedIn.
What it does
BiotechnologyManufacturingPharmaceutical
Funding, as listed
$34M raised in total
- Rounds4
- LatestGrant, May 2010
- Latest amountUSD 3,400,000
- Investors3, 3 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about GlycoVaxyn, field by field. Contact details are held but never shown.
The company
- Name
- GlycoVaxyn
- Type
- For profit
- Status
- Private
- Founded
- 2004
- Industry
- Hospital & Health Care
- Categories
- Biotechnology, Manufacturing, Pharmaceutical
Where
- Country
- Switzerland
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- People on LinkedIn
- 2
- LinkedIn followers
- 486
Funding, as listed
- Total
- $34,302,849 USD
- Rounds
- 4
- Latest round
- Grant
- Latest round date
- May 2010
- Latest amount
- 3,400,000 USD
- Investors
- 3
- Lead investors
- 3
- Listing status
- private
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
GlycoVaxyn may be growing as indicated by its acquisition by GSK, which suggests an expansion of its vaccine pipeline and potential access to greater resources. The acquisition by a major pharmaceutical company like GSK typically reflects a positive outlook on the acquired company's value and future capabilities. Furthermore, the spin-out of LimmaTech Bio from GlycoVaxyn post-acquisition implies that GlycoVaxyn's research and development efforts have been robust enough to generate new ventures, which is often a sign of a dynamic and innovative company environment.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Hospital & Health Care in Switzerland.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,795 companies in Switzerland and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.